Acrivon Therapeutics, Inc. (ACRV) carries a current, attributed analyst price-target set spanning roughly $7 to $19. Recent, verifiable targets include Maxim Group at $7, Oppenheimer and Piper Sandler each at $8, Gabelli at $8, Citizens JMP at $13, Jefferies at $14, and H.C. Wainwright at $19. The arithmetic mean of these seven targets is approximately $11, which is the central target used here. Because all current ratings are Buy, Outperform, or Overweight equivalents, the "consensus" is bullish in tone, but the $7-to-$19 spread shows analysts do not agree on magnitude.
Notable recent changes include Piper Sandler raising its target from $6 to $8 (January 2026), Oppenheimer assuming coverage with an Outperform rating and $8 target (June 2026), and Gabelli initiating at Buy with $8. The wide gap reflects differing views on how much credit to give the ACR-368 Phase 2b interim readout in serous endometrial cancer and the ACR-2316 dose-expansion data expected in 2027.
Shares of ACRV have recently traded near $1.72, within a 52-week range of roughly $1.27 to $3.56, with a market capitalization near $74 million. Moving to $11 would require upside of about 540%, a very large move by any standard and far above the stock's prior 52-week high. For a pre-revenue biotech, such a path is almost entirely dependent on clinical data, not on near-term earnings.
Acrivon has no product revenue and posts quarterly GAAP net losses in the high-teens of millions of dollars. The investment case therefore rests on its AP3 (Acrivon Predictive Precision Proteomics) platform and its two lead clinical assets. A positive interim analysis from ACR-368 — a CHK1/CHK2 inhibitor being studied in Phase 2b serous endometrial cancer, both as monotherapy and in combination — would be the most direct catalyst for a sustained repricing. The company also benefits from a balance sheet where enterprise value is negative, indicating net cash that exceeds the market capitalization, which reduces near-term dilution risk relative to many peers.
On a technical basis, ACRV trades in the lower portion of its 52-week range of roughly $1.27 to $3.56. The $1.27 area marks a notable prior low and potential support zone, while the $3.56 level represents a major resistance from the stock's prior high. Because the $11 target sits well above any established trading range, there are no meaningful resistance levels between the current price and the target — the gap reflects clinical catalysts rather than technical structure.
Analyst price targets typically reflect a roughly 12-month research horizon, though individual analysts may differ. The most important near-term item is the ACR-368 Phase 2b interim analysis in serous endometrial cancer, expected in the second half of 2026, followed by ACR-2316 dose-expansion data targeted for 2027. Investors should also track quarterly cash position and burn, analyst target revisions after any data readout, and broader biotech-sector sentiment, which influences how aggressively pre-revenue names are valued.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For traders following names like ACRV, these signals can help surface opportunities, monitor existing positions, and identify shifting trends more efficiently than manual screening. Explore the AI Daily Buy/Sell Signals to see how automated monitoring can complement your own research.
Can Acrivon Therapeutics (ACRV) reach $11? The question hinges on binary clinical outcomes rather than steady execution. The $11 central target, derived from seven current analyst targets ranging from $7 to $19, implies roughly 540% upside from a price near $1.72 — a move that would require meaningfully positive ACR-368 Phase 2b data and continued progress on ACR-2316. A net cash balance and a uniformly bullish analyst base provide a foundation, but pre-revenue biotech investing carries outsized risk, and the wide target dispersion underscores that even supportive analysts disagree sharply on value. Investors should watch the ACR-368 interim readout and any subsequent analyst revisions as the key signposts.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ACRV has been loosely correlated with IMRX. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ACRV jumps, then IMRX could also see price increases.
| Ticker / NAME | Correlation To ACRV | 1D Price Change % | ||
|---|---|---|---|---|
| ACRV | 100% | -0.63% | ||
| IMRX - ACRV | 51% Loosely correlated | +5.48% | ||
| ALLR - ACRV | 48% Loosely correlated | -3.49% | ||
| CRMD - ACRV | 43% Loosely correlated | -1.83% | ||
| DNA - ACRV | 41% Loosely correlated | -2.91% | ||
| SANA - ACRV | 38% Loosely correlated | -1.42% | ||
More | ||||